(NYSE: ABBV) AbbVie's forecast annual revenue growth rate of 11.33% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.
AbbVie's revenue in 2020 is $40,650,000,000.On average, 5 Wall Street analysts forecast ABBV's revenue for 2021 to be $95,388,908,687,316, with the lowest ABBV revenue forecast at $93,647,346,532,498, and the highest ABBV revenue forecast at $98,703,593,782,288. On average, 5 Wall Street analysts forecast ABBV's revenue for 2022 to be $102,127,183,207,204, with the lowest ABBV revenue forecast at $98,553,582,956,378, and the highest ABBV revenue forecast at $106,237,666,909,462.
In 2023, ABBV is forecast to generate $95,711,024,286,543 in revenue, with the lowest revenue forecast at $92,604,330,084,112 and the highest revenue forecast at $99,619,542,236,962.